Several factors are currently considered to select the best treatment after CDK4/6is: the presence or absence of driver mutations (ESR1, PIK3CA, germline BRCA1-2), the duration of exposure to CDK4/6is, the burden and sites of metastatic disease, comorbidities, patient preference and the availability of clinical trials. This evidence concerns the gene ESR1 and metastatic neoplasm.